



PATENT
Attorney Docket No. UM-06645

RECEIVED

SEP 25 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gabriel Nunez *et al.*

Serial No.: 10/014,268 *269*

Filed: 10/26/01

Entitled: NOD2 Nucleic Acids and Proteins

Group No.:

Examiner:

INFORMATION DISCLOSURE
STATEMENT TRANSMITTAL

RECEIVED

SEP 23 2003

TECHNOLOGY CENTER R3700


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: September 12, 2003

By:



Mary Ellen Waite

Sir or Madam:


Enclosed please find an Information Disclosure Statement and Form PTO-1449, including copies of the references contained thereon, for filing in the U.S. Patent and Trademark Office.

Applicant's believe no fee is required. This Information Disclosure Statement and PTO Form-1449 are being filed before the issuance of a first Office Action. If the Commissioner deems otherwise, the Commissioner is hereby authorized to charge any additional fee or credit overpayment to our Deposit Account No. 08-1290. **An originally executed duplicate of this transmittal is enclosed for this purpose.**

Dated: September 12, 2003


Tanya A. Arenson
Registration No. 47,391

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
608/218-6900



SEP 16 2003

UM-06645
September 12, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Application of: Nunez *et al.*

Serial No.: 10/014,269

Group No.: SEP 25 2003

Filed: 10/26/01

Examiner:

Entitled: NOD2 NUCLEIC ACIDS AND PROTEINS

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231, on September 12, 2003.

By: 
Mary Ellen Waite

Sir or Madam:

The citations listed below, copies attached, may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

- The following publications were cited in the International Search reports of co-pending PCT Applications WO 02/44426 and WO 02/36773:
 - WO 01/72822;
 - WO 99/64576;
 - WO 99/40102;
 - WO 01/90156;

RECEIVED

SEP 23 2003

TECHNOLOGY CENTER R3700

- Ogura et al., "A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease," Nature Vol 411:603 [2001];
- Hugot et al., "Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease," Nature 411:6837 [2001];
- Inohara et al., "The NOD: A signaling module that regulates apoptosis and host defense against pathogens," Oncogene, 20:6473 [2001];
- Ogura et al., "Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappa B," J. Biol. Chem. 276:4812 [2001];
- Database EMBL, Human NOD2 protein mRNA, Database accession number AF178930;
- Database EMBL, June 7, 1999 "Sequencing of human chromosome 16," Database accession no. AC007728;
- Database EMBL May 18, 1999 "Use of BAC end sequences from library RPCI-11 for sequence-ready map building," Database Accession No. AQ534686;
- Hugot et al., "Mapping of a susceptibility locus for Crohn's disease on chromosome 16," Nature 379:821 [1996];
- Miceli-Richard et al., "CARD15 mutations in Blau syndrome," Nature Genetics 29:19 [2001]; and
- Inohara et al., "Nods: A family of cytosolic proteins that regulate the host response to pathogens," Curr. Opin. Microbiol. 5:76 [2002].

The following printed publications are referred to in the body of the specification:

- Aderem and Ulevitch, Nature, 406:785-787 [2000];
- Philpott *et al.*, J. Immunol., 165:903-914 [2000];
- Leister and Katagiri, Plant J., 22:345-354 [2000];
- Hugot *et al.*, Nature 379:821 [1996];

- Chou *et al.*, Cell, 94:171 [1998];
- Kobe and Deisenhofer, Curr. Opin. Struct Biol., 5:409-416 [1995];
- Zou *et al.*, J. Bio. Chem. 274: 11549-11556 [1999];
- Schwandner *et al.*, J. Biol. Chem., 274: 17406-17409 [2000];
- Inohara *et al.*, J. Biol. Chem. 274: 14560-14568 [1999];
- Li *et al.*, Cell 91: 479-489 [1997];
- Snivasula *et al.*, Mol. Cell 1: 949-957 [1998];
- Hu *et al.*, J. Bio. Chem. 273: 33489-34494 [1998];
- Inohara *et al.*, J. Biol. Chem. 273: 12296-12300 [1998];
- McCarthy *et al.*, J. Bio. Chem. 273, 16968-16975 [1998];
- Parniske *et al.*, Cell 91: 821-832 [1997];
- Dixon *et al.*, Proc. Natl. Acad. Sci. U. S. A. 97: 8807-8814 [2000];
- Aliprantis *et al.*, Science, 285:736-739 [1999];
- Chow *et al.*, J. Biol. Chem., 274:10689-10692 [2000];
- Bertin *et al.*, J. Biol. Chem., 274:12955-12958;
- McCarthy *et al.*, J. Biol. Chem., 273:16968-16975;
- Thome *et al.*, Curr. Biol., 8:885-888 [1998];
- Inohara *et al.*, J. biol. Chem., 275:27823-27831 [2000];
- Shimada *et al.*, Int. Immunol., 11:1357-1362 [1999];
- Huang *et al.*, PNAS, 94:12829-12832 [1997];
- Medzhitov *et al.*, Mol. Cell, 2:253-258 [1998];
- Hsu *et al.*, Immunity, 4:387-396 [1996];
- Yamaoka *et al.*, Cell 93: 1231-1240 [1998];
- Hu *et al.*, EMBO J. 18: 3586-3595 [1999];
- Karin, J. Biol. Chem. 274: 27339-27342 [1999];
- Hofmann *et al.*, Trends Biochem. Sci. 22: 155-156 [1997];
- MacCorkle *et al.*, Proc. Nat. Acad. Sci. U. S. A. 95: 3655-3660 [1998];

UM-06645
September 12, 2003


- Yang *et al.*, Nature, 395:284-288 [1998];
- Zou *et al.*, Cell, 90:405-413 [1997];
- Poltorak *et al.*, Science, 282:2085 [1998];
- Takeuchi *et al.*, Immunity, 4:443 [1999];
- Rietschel *et al.*, Curr Top. Microbiol. Immunol., 216:39-81 [1997];

Applicants have become aware of the following printed publications which may be material to the examination of this application:

- Cho *et al.*, Inflammatory Bowl Diseases 3:186 [1997];
- Cho *et al.*, Proc. Natl. Acad. Sci. 95:7502 [1998];
- Brant *et al.*, Gastroenterology 115:1056 [1998];
- Cho *et al.*, Hum. Mol. Gent. 9:1425 [2000];
- Cavanaugh *et al.*, Ann. Hum. Gent. 62:291 [1998];
- Tysk *et al.*, Gut 29:990 [1988].

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: September 12, 2003



Tanya A. Arenson
Reg. No. 47, 391
MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
608 218-6900

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: UM-06645	Serial No.: 10/014,269
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Applicant: Gabriel Nunez et al.	
(37 CFR § 1.98(b))				Filing Date: 10/26/01	Group Art Unit:

O I P E
J C 103
SEP 16 2003
P A T E N T
S Y S T E M

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
-------------------	----------	------------------------	------------	----------------------	-------	----------	-------------

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No
	1	WO 01/72822	4 October 01	PCT				X
	2	WO 99/64576	16 December 99	PCT				
	3	WO 99/40102	12 August 99	PCT				
	4	WO 01/90156	22 November 01	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

5	Ogura et al., "A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease," Nature Vol 411:603 [2001]
6	Hugot et al., "Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease," Nature 411:6837 [2001]
7	Inohara et al., "The NOD: A signaling module that regulates apoptosis and host defense against pathogens," Oncogene, 20:6473 [2001]
8	Ogura et al., "Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappa B," J. Biol. Chem. 276:4812 [2001]
9	Database EMBL, Human NOD2 protein mRNA, Database accession number AF178930
10	Database EMBL, June 7, 1999 "Sequencing of human chromosome 16," Database accession no. AC007728
11	Database EMBL May 18, 1999 "Use of BAC end sequences from library RPCI-11 for sequence-ready map building," Database Accession No. AQ534686
12	Hugot et al., "Mapping of a susceptibility locus for Crohn's disease on chromosome 16," Nature 379:821 [1996]
13	Miceli-Richard et al., "CARD15 mutations in Blau syndrome," Nature Genetics 29:19 [2001]
14	Inohara et al., "Nods: A family of cytosolic proteins that regulate the host response to pathogens," Curr. Opin. Microbiol. 5:76 [2002]
15	Aderem and Ulevitch, Nature, 406:785-787 [2000]
16	Philpott et al., J. Immunol., 165:903-914 [2000]
17	Leister and Katagiri, Plant J., 22:345-354 [2000]
18	Hugot et al., Nature 379:821 [1996]
19	Chou et al., Cell, 94:171 [1998]
20	Kobe and Deisenhofer, Curr. Opin. Struct Biol., 5:409-416 [1995]
21	Zou et al., J. Bio. Chem. 274: 11549-11556 [1999]
22	Schwandner et al., J. Biol. Chem., 274: 17406-17409 [2000]
23	Inohara et al., J. Biol. Chem. 274: 14560-14568 [1999]
24	Li et al., Cell 91: 479-489 [1997]
25	Snivasula et al., Mol. Cell 1: 949-957 [1998];
26	Hu et al., J. Bio. Chem. 273: 33489-34494 [1998]
27	Inohara et al., J. Biol. Chem. 273: 12296-12300 [1998]

*RECEIVED**SEP 23 2003**TECHNOLOGY CENTER R3700**RECEIVED**SEP 25 2003**TECH CENTER 1600/2900*

Examiner: Date Considered:

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)			U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: UM-06645	Serial No.: 10/014,269
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)			Applicant: Gabriel Nunez et al.		
(37 CFR § 1.98(b))			Filing Date: 10/26/01		Group Art Unit:
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
	28	McCarthy et al., J. Bio. Chem. 273, 16968-16975 [1998]			
	29	Parniske et al., Cell 91: 821-832 [1997]			
	30	Dixon et al., Proc. Natl. Acad. Sci. U. S. A. 97: 8807-8814 [2000]			
	31	Aliprantis et al., Science, 285:736-739 [1999]			
	32	Chow et al., J. Biol. Chem., 274:10689-10692 [2000]			
	33	Bertin et al., J. Biol. Chem., 274:12955-12958 (1999)			
	34	Thome et al., Curr. Biol., 8:885-888 [1998]			
	35	Inohara et al., J. biol. Chem., 275:27823-27831 [2000]			
	36	Shimada et al., Int. Immunol., 11:1357-1362 [1999]			
	37	Huang et al., PNAS, 94:12829-12832 [1997]			
	38	Medzhitov et al., Mol. Cell, 2:253-258 [1998]			
	39	Hsu et al., Immunity, 4:387-396 [1996]			
	40	Yamaoka et al., Cell 93: 1231-1240 [1998]			
	41	Hu et al., EMBO J. 18: 3586-3595 [1999]			
	42	Karin, J. Biol. Chem. 274: 27339-27342 [1999]			
	43	Hofmann et al., Trends Biochem. Sci. 22: 155-156 [1997]			
	44	MacCorkle et al., Proc. Nat. Acad. Sci. U. S. A. 95: 3655-3660 [1998]			
	45	Yang et al., Nature, 395:284-288 [1998]			
	46	Zou et al., Cell, 90:405-413 [1997]			
	47	Poltorak et al., Science, 282:2085 [1998]			
	48	Takeuchi et al., Immunity, 4:443 [1999]			
	49	Rietschel et al., Curr Top. Microbiol. Immunol., 216:39-81 [1997]			
	50	Cho et al., Inflammatory Bowl Diseases 3:186 [1997]			
	51	Cho et al., Proc. Natl. Acad. Sci. 95:7502 [1998]			
	52	Brant et al., Gastroenterology 115:1056 [1998]			
	53	Cho et al., Hum. Mol. Gent. 9:1425 [2000]			
	54	Cavanaugh et al., Ann. Hum. Genet. 62:291 [1998]			
	55	Tysk et al., Gut 29:990 [1988]			

RECEIVED

SEP 25 2003

Examiner:

Date Considered:

TECH CENTER 1600/2900

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

SEP 23 2003

TECHNOLOGY CENTER R3700